Skip to content

RNAseq Analysis of Microbial Gene Expression in Necrotizing Soft Tissue Infections

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02025816
Acronym
NSTI
Enrollment
35
Registered
2014-01-01
Start date
2013-12-31
Completion date
2019-06-30
Last updated
2019-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Necrotizing Soft Tissue Infections

Brief summary

Hypothesis: We hypothesize that RNAseq will allow us to learn more about the causative agents of necrotizing soft tissue infections (NSTI) and risk factors involved in acquiring these devastating infections Tissue biopsies will be obtained from consented patients admitted with NSTI. Biopsies will be used for standard clinical analysis of bacterial species present or stored for later RNA sequencing. RNA sequencing will identify bacteria that are present within the infection site that may not be detected using standard culture techniques as well as reveal bacterial gene expression profiles within the NSTI site. Medical charts will also be reviewed for basic patient information as well as wound care management practices. We hope to identify bacterial species commonly present in these types of infections as well as risk factors predisposing individuals to NSTI's.

Interventions

None listed

Sponsors

Texas Tech University Health Sciences Center
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient or LAR agrees to the procedure and signs informed consent form * Patient is at least 18 yrs of age * Patient has been diagnosed with an NSTI

Exclusion criteria

* Patient not willing to undergo additional tissue biopsies for RNA sequencing analysis

Design outcomes

Primary

MeasureTime frame
Percentage of patients with non-culturable, anaerobic bacterial species colonization of NSTI2-6 wks (duration of hospitalization)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026